Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Triple-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01964924
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast Carcinoma+4 more
National Cancer Institute (NCI) 37
Early research (Phase 1)Active Not RecruitingNCT06781983
What this trial is testing

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Innate Pharma 145
Testing effectiveness (Phase 2)Active Not RecruitingNCT03911973
What this trial is testing

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Kari Wisinski 37
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07080619
What this trial is testing

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Who this might be right for
TNBC - Triple-Negative Breast CancerHR+ Breast Cancer
Tianjin ConjuStar Biologics Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT04742959
What this trial is testing

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorCholangiocarcinomaHER2-negative Breast Cancer+8 more
TransThera Sciences (Nanjing), Inc. 203
Early research (Phase 1)Study completedNCT02027376
What this trial is testing

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 12
Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6
Not applicableUnknownNCT06261918
What this trial is testing

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Who this might be right for
Breast CancerMetabolic Syndrome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120
Testing effectiveness (Phase 2)Study completedNCT03098550
What this trial is testing

Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Who this might be right for
Advanced Cancer
Bristol-Myers Squibb 105
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Early research (Phase 1)Ended earlyNCT05069935
What this trial is testing

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Fate Therapeutics 16
Testing effectiveness (Phase 2)Study completedNCT00733408
What this trial is testing

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more
University of Washington 59
Early research (Phase 1)Active Not RecruitingNCT07038369
What this trial is testing

ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Who this might be right for
Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more
Atavistik Bio, Inc 134
Testing effectiveness (Phase 2)Looking for participantsNCT05491083
What this trial is testing

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorTriple Negative Breast Cancer
National University Hospital, Singapore 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Not applicableAvailableNCT01216124
What this trial is testing

Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Local Advanced Breast Cancer
Fudan University
Large-scale testing (Phase 3)Looking for participantsNCT03671044
What this trial is testing

Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer
Jina Pharmaceuticals Inc. 657
Early research (Phase 1)Ended earlyNCT05827614
What this trial is testing

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Who this might be right for
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more
Boundless Bio, Inc. 85
Next Page